Blogs | | Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Despite that, 50% of patients relapse after CAR-T therapy, and curative options for patients who relapse after CD19 CAR-T are limited, with no standard approach to cure.